New injection JMT106 enters first human tests for advanced cancers
NCT ID NCT07275073
First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This early-phase study tests a new drug called JMT106 in about 200 adults with advanced solid tumors (including lung and liver cancer) who have run out of standard options. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the drug alone, and the study will monitor side effects and anti-cancer activity for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affilicated Hospital,Zhejiang University School of Medicine
RECRUITINGZhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.